- In 2019, Hemptown USA expects to work on expanding its growing capacity to ensure the production of over one million pounds of biomass
- This is a part of the company’s expansion strategy, which aims to boost Hemptown’s hemp farming capacity to 2,500 acres by 2020
- Hemptown is also working on the development of its premium CBD and CBG oil products, as well as isolates
Hemptown USA, a proven grower of full-spectrum hemp biomass, anticipates a significant growing capacity expansion in 2019, as detailed by company founder and chairman Rod Wolterman in a CFN interview (http://ibn.fm/vErJU). According to Wolterman, Hemptown farmed 110 acres in 2018. The enterprise anticipates scaling up in 2019 to reach a capacity of 1,000 to 1,500 acres. This capacity is expected to enable Hemptown to produce in excess of one million pounds of biomass.
This announcement is in line with the Hemptown USA growth strategy. By 2020, the company expects to boost its hemp farming footprint to 2,500 acres located in several states. In addition, more emphasis will be placed on increasing the in-house CBD and CBG extraction capabilities. Through strategic partnerships, the company also anticipates expanding its distribution and growing operations globally.
Hemptown focuses its efforts on multiple cannabinoids, going beyond CBD. The company has a proprietary genetics program with strains that are high in various alternative cannabinoids like CBG and CBN. Currently, Hemptown holds an agreement for one million rare CBG seeds to be grown in 2019 and the coming years.
The premium seed genetics ensure concentrations of THC that remain below 0.3 percent and a high CBD yield of up to 20 percent. Due to strategic partnerships and access to rare seeds, Hemptown aims to establish itself as a leading CBG producer in 2019.
CBG is currently considered a minor cannabinoid, because it’s not present in large quantities in traditional plants. Cannabinoid manufacturers are carrying out genetic programs to modify strains and maximize yields. In terms of health benefits, CBG produces results that are comparable to those of CBD. It has a positive impact on the functioning of the endocannabinoid system – a mechanism that works to keep the body in a balanced state of homeostasis. Research suggests that CBG is an effective option for the treatment of glaucoma (http://ibn.fm/q9P4z) or inflammatory bowel disease (http://ibn.fm/3UrPx), is a powerful antibacterial agent (http://ibn.fm/E1abH) and may even have some cancer fighting properties (http://ibn.fm/jRCoq). Scientific work is ongoing to identify the full scope of CBG effects, as well as the health benefits resulting from a combination of CBG and other cannabinoids.
In 2019 and the years beyond, Hemptown anticipates being capable of producing custom, proprietary and full-spectrum CBD and CBG oils, as well as isolates.
For more information, visit the company’s website at www.HemptownUSA.com
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.